Streetbeat News

Revenues

XFOR

The FDA has approved X4 Pharmaceuticals Inc's (NASDAQ:XFOR) Xolremdi (mavorixafor) for patients 12 and older with WHIM syndrome, marking it as the first therapy for this rare immunodeficiency disorder. The approval is based on Phase 3 trial results showing significant improvements in neutrophil and lymphocyte counts and a reduction in infections. X4 Pharmaceuticals has also received a Rare Pediatric Disease Priority Review Voucher and set the annual cost of Xolremdi at $496,400 for patients over 50 kg and $372,300 for those 50 kg or under. Analysts predict the therapy could generate $54.6 million in sales by 2024, potentially growing to $450.9 million by 2027.

Portfolio Pulse from Vandana Singh

April 29, 2024 | 4:10 pm

AEO

Recent analyst ratings for American Eagle Outfitters (NYSE:AEO) show a diverse range of perspectives, with an updated average 12-month price target of $26.2, reflecting a 12.06% increase from the previous target. Analysts from firms like Barclays, JP Morgan, and Morgan Stanley have adjusted their ratings and price targets, indicating a generally positive outlook despite some bearish views. American Eagle's financial performance shows notable revenue growth but challenges in profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 4:00 pm

WDC

Western Digital (NASDAQ:WDC) has received diverse analyst ratings over the last three months, with a recent shift towards more bullish outlooks. The average 12-month price target for WDC has been raised to $84.3, indicating a 23.41% increase from the previous target. Analysts from firms like Argus Research, Evercore ISI Group, and Morgan Stanley have adjusted their ratings and price targets, reflecting optimism about the company's future performance. Despite this, Western Digital faces challenges such as a decline in revenue growth and below-average financial health indicators compared to industry peers.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 4:00 pm

BUZZ

SOFI

STCE

SoFi Technologies Inc. reported fiscal first-quarter 2024 results with a 26% year-on-year increase in adjusted revenue to $580.648 million, surpassing consensus estimates. Adjusted EPS was $0.02, beating the consensus of $0.01. The company added 622,000 new members, reaching over 8.1 million, and introduced over 989,000 new products, totaling over 11.8 million. Adjusted EBITDA rose by 91% Y/Y to $144.39 million. SoFi projects Q2 adjusted net revenue of $555 million to $565 million and adjusted EBITDA of $115 million to $125 million. For the full year 2024, it expects at least 50% growth in Tech Platform and Financial Services segments, with Lending revenue at 92% to 95% of 2023 levels, and an adjusted EBITDA margin of approximately 25%. SoFi stock is down 10% at $7.08. Investors can also gain exposure to SoFi through VanEck Social Sentiment ETF (BUZZ) and Schwab Strategic Trust Schwab Crypto Thematic ETF (STCE).

Portfolio Pulse from Anusuya Lahiri

April 29, 2024 | 4:00 pm

NFLX

A HarrisX survey indicates Netflix's ad-supported subscription tier is the second most popular in the U.S., suggesting over 20 million domestic subscribers. This growth signifies a successful shift towards ad revenue, with potential for further expansion as Netflix plans to eliminate the ad-free Basic plan in some markets. The survey also highlights the ad tier's role in attracting new subscribers, especially younger users, as Netflix focuses more on engagement and ad revenue in a slow-growth model.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 3:13 pm

RBLX

WMT

Walmart and Roblox have partnered to launch a virtual e-commerce experience within Roblox, allowing users to purchase physical goods directly in the game. This pilot test, running through May, enables users aged 13 or older in the U.S. to buy items from a virtual Walmart store and have them shipped to their real-world addresses. The initiative, which does not currently generate revenue for Roblox, aims to explore the potential of selling physical goods on the platform and could lead to Walmart expanding its e-commerce presence within Roblox.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 3:03 pm

ABBV

AbbVie (NYSE:ABBV) received mixed analyst ratings in the latest quarter, with an average 12-month price target of $189.75, reflecting a positive shift from the previous $184.00. Analysts' actions varied, with some raising and others lowering their price targets, indicating differing views on AbbVie's market performance. Despite this, AbbVie faces financial challenges, including a -5.42% decline in revenue growth and below-average profitability metrics, suggesting potential short-term investment risks.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 3:01 pm

AVB

AvalonBay Communities (NYSE:AVB) has been the subject of diverse analyst ratings over the last three months, with a recent shift towards more bullish sentiments. The latest analysis shows an average 12-month price target of $198.75, marking a 2.37% increase from the previous target. Analysts from firms like RBC Capital, Piper Sandler, Truist Securities, Mizuho, Morgan Stanley, Goldman Sachs, and Barclays have updated their ratings and price targets, reflecting various adjustments based on the company's performance and market conditions. AvalonBay Communities, with a significant portfolio of apartment communities, has shown impressive financial metrics such as a 5.23% revenue growth rate, a net margin of 34.1%, and strong ROE and ROA figures, indicating robust financial health and market presence.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 3:00 pm

AVTR

Ten analysts have recently updated their ratings on Avantor (NYSE:AVTR), showing a mix of bullish and somewhat bullish sentiments, with a shift towards more positive ratings in the last 30 days. The average 12-month price target for AVTR has increased to $27.9, up from $25.50, indicating a positive outlook on the stock. Avantor, serving various industries with its products and services, faces challenges in revenue growth and debt management but excels in net margin. Analysts' actions, ranging from raising to lowering ratings and price targets, reflect their evolving view on Avantor's market performance.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 2:01 pm

AXSM

Axsome Therapeutics (NASDAQ:AXSM) has received diverse analyst ratings over the last three months, with a current average 12-month price target of $131.89, reflecting a 6.52% increase from the previous average of $123.82. The company, a clinical-stage biopharmaceutical focused on CNS disorders, has shown a revenue growth of 193.5% as of December 31, 2023, but struggles with profitability and operational efficiency, indicated by a net margin of -137.92% and ROE of -42.85%.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 2:01 pm